Clinical Trials Logo

Colorectal Cancer clinical trials

View clinical trials related to Colorectal Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03938623 Active, not recruiting - Colorectal Cancer Clinical Trials

Teaching General Practitioners to Use the Patient-centered Approach When Suggesting Colorectal Cancer Screening

Start date: January 24, 2018
Study type: Observational

Context : Colorectal cancer (CRC) mass screening has been implemented in France since 2008. Participation rates remain too low. The objective of this study is to test if the implementation of a training course focused on communication skills (whether in-person or e-learning) among general practitioners (GP) would increase the delivery of gFOBT and CRC screening participation among the target population of each participating GP. Method : Pragmatic controlled cluster randomized trial with 2 parallel groups: Control versus Educational Intervention Intervention ; six hour educational training either in person or through e-learning The Main objective: is to evaluate the effectiveness of an educational intervention teaching physicians the patient-centered approach, either in-person or through e-learning, by evaluating their patients' participation in colorectal cancer (CRC) screening for all risk categories.

NCT ID: NCT03907579 Active, not recruiting - Colorectal Cancer Clinical Trials

Screen to Save: A Colorectal Cancer Educational Intervention

Start date: March 11, 2017
Phase: N/A
Study type: Interventional

The purpose of this research is to understand if an educational program about colorectal cancer helps improve people's knowledge of colorectal cancer prevention and screening and their intention to get screened for colorectal cancer.

NCT ID: NCT03904732 Active, not recruiting - Colorectal Cancer Clinical Trials

Study to Develop a Prediction Model to Understand the Effect of Low-dose Aspirin on Cancer That Develops in the Colon and/or the Rectum, Diseases That Affects the Heart or Blood Vessels and Safety Outcomes in European Countries. The Study is Also Called PEACOS Model EU

Start date: April 15, 2019
Study type: Observational

In this study researchers want to learn more about the effect of low-dose Aspirin on cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine before the anus), diseases that affects the heart or blood vessels and safety outcomes. Study will focus on two groups of adults aged 50-59 and 60-69 years having an increased risk of heart and/or blood vessel disease who are taking either low-dose aspirin or no low-dose aspirin for heart and/or blood vessel disease prevention. The model will be based on information publicly available either on government organization websites or in scientific journals. Based on these data researchers will focus in a first step to build a model of 2 million adults (1 million for each age group) for the UK population and in a second step, the model will be modified for use with other European countries, to reflect the epidemiology and guidelines for aspirin use in these countries.

NCT ID: NCT03806244 Active, not recruiting - Colorectal Cancer Clinical Trials

Feasibility of Stereotactic Navigation in Laparoscopic Surgery for Colorectal Cancer

Start date: January 3, 2019
Phase: N/A
Study type: Interventional

To evaluate the feasibility and precision of stereotaxic navigation in laparoscopic surgery for colorectal cancer.

NCT ID: NCT03728348 Active, not recruiting - Colorectal Cancer Clinical Trials

An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now

Start date: November 6, 2018
Study type: Observational

The primary objective is to confirm the specificity of a multi-target stool DNA test (mt-sDNA), Cologuard, in an average risk population, ages 45-49.

NCT ID: NCT03682744 Active, not recruiting - Breast Cancer Clinical Trials

CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)

Start date: September 13, 2018
Phase: Phase 1
Study type: Interventional

This is an open-label, dose-escalation, phase I trial of the safety and efficacy of anti-CEA intraperitoneal CAR-T infusions for treatment in patients with CEA-expressing adenocarcinoma peritoneal metastases or malignant ascites.

NCT ID: NCT03654950 Active, not recruiting - Colorectal Cancer Clinical Trials

Patient Empowerment With the Patient Perspective

Start date: June 1, 2018
Study type: Observational

The overall aim with this study is to gain a deeper understanding of patient perceptions regarding empowerment in relation to a health platform.

NCT ID: NCT03644459 Active, not recruiting - Colorectal Cancer Clinical Trials

Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101

Start date: April 3, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is evaluate the pharmacokinetics, pharmacodynamics, immunogenicity and anti-tumor effect of of fully human anti - VEGF monoclonal antibody LY00101 and explore the potential prognostic and predictive biomarkers. This study will not take into account the results of molecular-genetic tests of patients enrolled in the study

NCT ID: NCT03601351 Active, not recruiting - Colorectal Cancer Clinical Trials

MOR-1 Expression in Colorectal Cancer and Disease-free Survival Relationship. Five-year Follow-up.

Start date: May 4, 2018
Study type: Observational

Colorectal cancer (CRC) is a global burden and one of the most frequent types of cancer. Colorectal cancer therapy is complex and surgery remains the cornerstone for its treatment, combined with chemotherapy and radiotherapy. At diagnosis time, stage II / III is the predominant . There is a growing interest on the potential effect of perioperative anesthetic management on cancer growth and spread. Preclinical studies suggest that opioids could promote direct tumor growth, angiogenesis, metastasis and immunosuppression of cellular and humoral responses, mainly mediated by Mu opioid receptor 1 (MOR-1) activation. Association between increased expression of MOR-1and or perioperative opioids use and shorter DFS or OS has been demonstrated in lung, prostate, gastric and esophagus cancers. Furthermore a pooled analysis suggested that methylnaltrexone, a peripherally acting Mu-opioid receptor antagonist (PAMORA) was associated with increased survival in patients with advanced cancer. Thus, the expression of the MOR-1 is an indicator of poor prognosis in some cancer types, but its relevance in colon cancer is unknown. The hypothesis of this study is that the increased MOR-1expression in tumor samples from colorectal cancer could be associated to poor disease free survival. These findings would be of great clinical relevance in order to avoid perioperative opioid use in oncological patients. Moreover PAMORAs could be a valuable tool in perioperative antitumor treatment, since currently these drugs are currently used with confirmed tolerability and low adverse effects in the management of opioid-induced constipation (Opioid Induced Constipation-OIC). Besides MOR 1 expression could constitute a biomarker that guide the investigators to perform neoadjuvant therapy.

NCT ID: NCT03575117 Active, not recruiting - Colorectal Cancer Clinical Trials

Views on Cancer Prevention and Daily Lifestyle

Start date: May 1, 2018
Phase: N/A
Study type: Interventional

This study is to assess how a theoretically guided mHealth communication informed by evidence of thoughts and affect about colorectal cancer can enhance how an existing mHealth (cell/mobile based text messaging health promotion) intervention increased physical activity in healthy adults.